Save Product
Product Details
Source
Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) is a neutralizing mouse monoclonal antibody produced from hybridoma.
Antibody Type
Hybridoma Monoclonal
Clone
Y45
Isotype
Mouse IgG1, Kappa
Host Species
Mouse
Immunogen
Recombinant FMC63 scFv expressed in HEK293 cells
Conjugate
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
Specificity
This antibody specifically recognizes the FMC63 scFv antigen-recognition domain in FMC63-derived CARs.
Application
Flow Cytometry (Evaluation of Anti-CD19 (FMC63 scFv) CAR Expression).
Recommended Dilution
1:50
Isotype Control
The isotype control is sold separately; please refer to Cat. No. DNP-FM1A1 for product information.
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4) containing 0.5% BSA, with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 24 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-FACS
2e5 of Anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) FITC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (Cat. No. FM3-FY45) and isotype control respectively. FITC signal was used to evaluate the binding activity (QC tested).
Protocol
Non-specificity of FITC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (Cat. No. FM3-FY45) binding to CD3+ cells present in human PBMC. Human PBMCs were simultaneously stained with PE-labeled anti-CD3 antibody and FITC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (2 μL of the antibody stock solution corresponds to labeling of 5e5 cells in a final volume of 100 µL), washed and then analyzed with FACS. Both PE and FITC positive signals was used to evaluate the non-specific binding activity to human CD3+ cells (QC tested).
Protocol
Customer Reviews Writing Reviews
A***l2023-05-19
LikesMy team purchased the FITC-conjugated Anti-FMC63 antibody (FM3-FY45) to characterize a CAR-T cell line that we had developed. We used the antibody in our flow cytometry experiment, and we saw virtually no background signal in our negative control samples (0% and 1% FITC readout). We did, however, get beautiful results for our CAR-T cell line samples and were able to confirm successful transduction. The instructions for use in the CoA were very clear, and the recommended concentration was sufficient for our purposes. I am very interested in revisiting ACRO Biosystems for more antibody purchases in the future.- C***ó2021-09-28 LikesWe purchase the anti FMC63 to detect Chimeric antigen receptor (CAR) cells in patients treated with an academic CAR for lymphoma. We used the antibody to detect by flow cytometry the cells that express the CAR and the persistence of our modified T cells. We are extremely satisfied with the performance of the antibodies. We are developing new CAR and for sure we will use the antibodies from Acrobiosystems.
- L***a2021-08-25 LikesWe are a CAR-T therapy research group and we use FITC anti-FMC63 and FITC-Labeled Human CD19 protein to detect CAR19 cells both in patient blood and in vitro cultures by flow cytometry. The results obtained so far with both reagents are reliable and reproducible, with a clear and easy detection of positive population even when reagents are directly incubated with blood samples.
Background
Recent Advances
Contact Us
メールアドレス
order.jp@acrobiosystems.com
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
Drug Candidate Licensing
